NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Iambic Therapeutics, Inc. (IAM) Stock Analysis

Iambic Therapeutics, Inc. (IAM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

IAM

$15.80

−$0.21 (−1.31%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IAM with… →

IAM Key Statistics

As of Oct 21, 2026
Trading
Open
$15.50
Previous Close
$16.01
Day's Range
15.00–17.00
52-Week Range
14.10–25.00
Volume
478.11K
Valuation
Market Cap
$748.93M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
41.04
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.69
Financials (FY)
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
47.40M
Dividend and dates
Avg Volume
2.08M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Iambic Therapeutics, Inc. (IAM) has a market capitalization of $748.93M.

IAM Valuation vs Biotechnology Median

Median of 608 stocks
MetricIAMBiotechnology medianvs median
P/S ratio41.0413.303.1x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Iambic Therapeutics, Inc. (IAM) at $748.93M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 171 employees.

IAM last closed at $15.80 on October 21, 2026. That is −$0.21 (−1.31%) against the previous close. The 52-week range on file runs from $14.10 to $25.00. The latest close sits 12.06% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $18.25M. Trailing earnings per share are −2.69.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 41.04 times revenue. On price-to-sales that is 3.1 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Growth & Income

No dividend is on file for IAM.

So far in 2026 the total return is −16.45%.

Peer Comparison

Iambic Therapeutics, Inc. (IAM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Iambic Therapeutics, Inc. IAM $748.93M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Iambic Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Iambic Therapeutics, Inc.

Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.

Visit website →